跳至主要内容
临床试验/CTRI/2023/03/050809
CTRI/2023/03/050809尚未招募4 期

A Single Centric, Open-Label, Non-Randomized Phase IV Post-Marketing Surveillance Study to Measure the Efficacy and Safety of Dr. Ortho Capsules in Subjects Suffering from Knee Pain, Stiffness in Joints, Arthritis, Bulky Shoulder and Inflammation in Joints, Acute Sports Injury, Strains & Sprain

Divisa Herbals Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age between 18 - 80 Years
  • 2.Subjects suffering from knee pain and joint pain and arthritis
  • 3.Subjects suffering from acute sports injury, strains, sprain, chronic arthritis, back pain, knee pain, and other joint pain.
  • 4.Willingness to take part in study and able to attend all scheduled visits
  • 5.Subjects willing to sign ICF
  • 6.Subjects willing to refrain taking any other similar medication during the study period.

排除标准

  • 1.Pregnant, breastfeeding, subjects undergone any surgery and else taken part in any clinical trial
  • 2.Participation in any other clinical study (device or drug) within 30 days prior to Screening;
  • 3.Subjects with clinically significant serious cardiovascular, cerebrovascular, respiratory, hepatic, renal disease, congenital or any other disorder
  • 4.Subject with abnormal lab values detected at the time of screening shall be excluded.
  • 5.A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the investigational product.
  • 6.Pre-existing systemic disease necessitating long-term medications.
  • 7.Genetic and endocrinal disorder
  • 8.Not willing to Sign the ICF or give the consent

研究者

发起方
Divisa Herbals Pvt. Ltd.

相似试验